Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase
Abstract A novel series of hybrid analogues of monastrol-1,3,5-triazine were designed and developed via one-pot synthesis using Bi(NO3)3 as a catalyst. Entire compounds were evaluated for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast cancer), HL-60 (Human promyelocytic leuk...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-05934-5 |
| _version_ | 1818856137336815616 |
|---|---|
| author | Jitendra Kumar Srivastava Girinath G. Pillai Hans Raj Bhat Amita Verma Udaya Pratap Singh |
| author_facet | Jitendra Kumar Srivastava Girinath G. Pillai Hans Raj Bhat Amita Verma Udaya Pratap Singh |
| author_sort | Jitendra Kumar Srivastava |
| collection | DOAJ |
| description | Abstract A novel series of hybrid analogues of monastrol-1,3,5-triazine were designed and developed via one-pot synthesis using Bi(NO3)3 as a catalyst. Entire compounds were evaluated for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast cancer), HL-60 (Human promyelocytic leukemia), HepG2 (Hepatocellular carcinoma) and MCF 12A (normal epithelial breast cell line) using MTT assay, where they showed highest inhibitory activity against MCF-7. The molecules were also found to be non-toxic to MCF 12A cells. These molecules showed considerable inhibitory percentage against Epidermal Growth Factor Receptor tyrosine kinase (EGFR-TK), in in-vitro assay. Molecular docking study was carried out on the analogs and reference compound (Erlotinib) into the ATP binding site of EGFR-TK domain (PDB ID:1M17) to elucidate vital structural residues necessary for bioactivity. The effect of most active compound 7l was also estimated in-vivo in DMBA induced mammary tumor in female Sprague-Dawley rats. The effect of anti-breast cancer effect of 7l was quantified on the basis of tumour incidence, body weight and tumor volume in DMBA-induced rats. Its effect on biochemical parameters, such as antioxidant status (SOD, CAT, GPX and GSH) and lipid peroxidation was also studied. The compound 7l showed inhibition of EGFR downstream signalling in the western blot analysis. |
| first_indexed | 2024-12-19T08:19:43Z |
| format | Article |
| id | doaj.art-a3f39bb0c73b423ba93335c416a0a7bc |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T08:19:43Z |
| publishDate | 2017-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-a3f39bb0c73b423ba93335c416a0a7bc2022-12-21T20:29:25ZengNature PortfolioScientific Reports2045-23222017-07-017111810.1038/s41598-017-05934-5Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinaseJitendra Kumar Srivastava0Girinath G. Pillai1Hans Raj Bhat2Amita Verma3Udaya Pratap Singh4Drug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & SciencesInstitute of Chemistry, University of TartuDepartment of Pharmaceutical Sciences, Dibrugarh UniversityDrug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & SciencesDrug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & SciencesAbstract A novel series of hybrid analogues of monastrol-1,3,5-triazine were designed and developed via one-pot synthesis using Bi(NO3)3 as a catalyst. Entire compounds were evaluated for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast cancer), HL-60 (Human promyelocytic leukemia), HepG2 (Hepatocellular carcinoma) and MCF 12A (normal epithelial breast cell line) using MTT assay, where they showed highest inhibitory activity against MCF-7. The molecules were also found to be non-toxic to MCF 12A cells. These molecules showed considerable inhibitory percentage against Epidermal Growth Factor Receptor tyrosine kinase (EGFR-TK), in in-vitro assay. Molecular docking study was carried out on the analogs and reference compound (Erlotinib) into the ATP binding site of EGFR-TK domain (PDB ID:1M17) to elucidate vital structural residues necessary for bioactivity. The effect of most active compound 7l was also estimated in-vivo in DMBA induced mammary tumor in female Sprague-Dawley rats. The effect of anti-breast cancer effect of 7l was quantified on the basis of tumour incidence, body weight and tumor volume in DMBA-induced rats. Its effect on biochemical parameters, such as antioxidant status (SOD, CAT, GPX and GSH) and lipid peroxidation was also studied. The compound 7l showed inhibition of EGFR downstream signalling in the western blot analysis.https://doi.org/10.1038/s41598-017-05934-5 |
| spellingShingle | Jitendra Kumar Srivastava Girinath G. Pillai Hans Raj Bhat Amita Verma Udaya Pratap Singh Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase Scientific Reports |
| title | Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase |
| title_full | Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase |
| title_fullStr | Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase |
| title_full_unstemmed | Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase |
| title_short | Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase |
| title_sort | design and discovery of novel monastrol 1 3 5 triazines as potent anti breast cancer agent via attenuating epidermal growth factor receptor tyrosine kinase |
| url | https://doi.org/10.1038/s41598-017-05934-5 |
| work_keys_str_mv | AT jitendrakumarsrivastava designanddiscoveryofnovelmonastrol135triazinesaspotentantibreastcanceragentviaattenuatingepidermalgrowthfactorreceptortyrosinekinase AT girinathgpillai designanddiscoveryofnovelmonastrol135triazinesaspotentantibreastcanceragentviaattenuatingepidermalgrowthfactorreceptortyrosinekinase AT hansrajbhat designanddiscoveryofnovelmonastrol135triazinesaspotentantibreastcanceragentviaattenuatingepidermalgrowthfactorreceptortyrosinekinase AT amitaverma designanddiscoveryofnovelmonastrol135triazinesaspotentantibreastcanceragentviaattenuatingepidermalgrowthfactorreceptortyrosinekinase AT udayapratapsingh designanddiscoveryofnovelmonastrol135triazinesaspotentantibreastcanceragentviaattenuatingepidermalgrowthfactorreceptortyrosinekinase |